"Antigen Presentation" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The process by which antigen is presented to lymphocytes in a form they can recognize. This is performed by antigen presenting cells (APCs). Some antigens require processing before they can be recognized. Antigen processing consists of ingestion and partial digestion of the antigen by the APC, followed by presentation of fragments on the cell surface. (From Rosen et al., Dictionary of Immunology, 1989)
| Descriptor ID |
D017951
|
| MeSH Number(s) |
G12.119 G12.450.050.400.070
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antigen Presentation".
Below are MeSH descriptors whose meaning is more specific than "Antigen Presentation".
This graph shows the total number of publications written about "Antigen Presentation" by people in this website by year, and whether "Antigen Presentation" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 2 | 2 |
| 1996 | 1 | 3 | 4 |
| 1997 | 0 | 3 | 3 |
| 1998 | 1 | 4 | 5 |
| 1999 | 1 | 5 | 6 |
| 2000 | 4 | 5 | 9 |
| 2001 | 3 | 2 | 5 |
| 2002 | 3 | 6 | 9 |
| 2003 | 1 | 5 | 6 |
| 2004 | 3 | 5 | 8 |
| 2005 | 2 | 4 | 6 |
| 2006 | 3 | 6 | 9 |
| 2007 | 1 | 4 | 5 |
| 2008 | 5 | 3 | 8 |
| 2009 | 4 | 7 | 11 |
| 2010 | 0 | 7 | 7 |
| 2011 | 0 | 7 | 7 |
| 2012 | 0 | 3 | 3 |
| 2013 | 0 | 5 | 5 |
| 2014 | 1 | 2 | 3 |
| 2015 | 1 | 1 | 2 |
| 2016 | 2 | 3 | 5 |
| 2017 | 1 | 4 | 5 |
| 2018 | 2 | 4 | 6 |
| 2019 | 1 | 6 | 7 |
| 2020 | 1 | 4 | 5 |
| 2021 | 1 | 6 | 7 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 3 | 3 |
| 2024 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antigen Presentation" by people in Profiles.
-
TFEB activation hallmarks antigenic experience of B lymphocytes and directs germinal center fate decisions. Nat Commun. 2024 Aug 14; 15(1):6971.
-
The biology and function of extracellular vesicles in immune response and immunity. Immunity. 2024 Aug 13; 57(8):1752-1768.
-
Incongruity between T cell receptor recognition of breast cancer hotspot mutations ESR1 Y537S and D538G following exogenous peptide loading versus endogenous antigen processing. Cytotherapy. 2024 03; 26(3):266-275.
-
Interleukin-7 potentiates MAPK10-elicited host-protective vaccine against Leishmania donovani. Cytokine. 2024 02; 174:156475.
-
Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor-Positive Breast Cancer. Cancer Res. 2023 10 02; 83(19):3284-3304.
-
NLRP3 agonist enhances radiation-induced immune priming and promotes abscopal responses in anti-PD1 resistant model. Cancer Immunol Immunother. 2023 Sep; 72(9):3003-3012.
-
Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101). Clin Cancer Res. 2022 12 01; 28(23):5079-5087.
-
Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses. J Immunother Cancer. 2022 01; 10(1).
-
Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer. Nat Commun. 2021 09 21; 12(1):5563.
-
CD303 (BDCA-2) - a potential novel target for therapy in hematologic malignancies. Leuk Lymphoma. 2022 01; 63(1):19-30.